Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation

Journal of Hypertension

Volumn 33, Issue 7, 2015, Pages 1480-1486

  Okin, Peter M ^a   Hille, Darcy A ^b   Wachtell, Kristian ^c   Kjeldsen, Sverre E ^d   Boman, Kurt ^e   Dahlöf, Björn ^f   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF OSLO   (Norway)

^e UMEÅ UNIVERSITY   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Electrocardiography; Fibrillation; Hypertension; Hypertrophy

Indexed keywords

ATENOLOL; CREATININE; DIGOXIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN;

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PULSE PRESSURE; QRS INTERVAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; COMPLICATION; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; RISK;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL FIBRILLATION; BLOOD PRESSURE; DIGOXIN; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPOPROTEINS, HDL; LOSARTAN; MALE; MIDDLE AGED; RISK;

EID: 84942518858     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000559     Document Type: Article

References (34)

1. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-1046.
3. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
4. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
5. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
6. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythmia Electrophysiol 2013; 6:243-252.
7. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36:1115-1119.
8. Verdecchia P, Reboldi R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41:218-223.
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a populationbased cohort: the Framingham Heart Study. JAMA 1994; 271:840-844.
10. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart Study. Circulation 1994; 89:724-730.
11. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455-2461.
12. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123:1501-1508.
13. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DA. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160:1612-1617.
14. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833.
15. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl Med 2002; 347:1834-1840.
16. Camm AJ, Kirchof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
17. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
18. Domanski M, Fleg J, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 2005; 11:83-86.
19. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, for the Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail 2010; 16:191-195.
20. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incidence systolic heart failure. Circ Cardiovasc Qual Outcomes 2013; 6:525-533.
21. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-878.
22. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Abam IB, Colucci WS, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178-186.
23. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109:1509-1513.
24. Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H, for the RIKS-HIA group. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007; 63:959-971.
25. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF Study. J Am Coll Cardiol 2014; 64:660-668.
26. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013; 34:1481-1488.
27. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JGF, Butler J, Epstein AE, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013; 34:1489-1497.
28. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation: the LIFE Study. JAMA 2006; 296:1242-1248.
29. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Devereux RB. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE Study. Circ Arrhythmia Electrophysiol 2008; 1:337-343.
30. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997; 10:705-713.
31. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
32. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37:161-186.
33. Snappin SM, Jiamg Q, Iglewicz B. Illustrating the impact of a timevarying covariate with an extended Kaplan-Meier estimate. The Am Statistician 2005; 59:301-307.
34. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertension: The LIFE Study. Eur Heart J 2010; 31:2271-2279.